Diet–Microbiome Synergy Drives Immunotherapy Efficacy in Obesity, Landmark Nature Study Reveals
Key Insights
A Nature (search) study identifies Lactobacillus johnsonii (search) as a key gut bacterium enriched by obesogenic diets that enhances anti-PD-1 immunotherapy response in mouse models.
Monocolonization with L. johnsonii combined with a high-fat diet produced striking anti-tumor effects, with complete tumor clearance in antibiotic-treated mice receiving supplementation.
The microbial metabolite desaminotyrosine (DAT) emerged as a potent immunomodulator that restored sensitivity to anti-PD-1 in diet-resistant models by potentiating CD8+ T cell function.
A groundbreaking study published in Nature (search) has uncovered a critical mechanistic synergy between diet and the gut microbiome that explains why obesity is associated with enhanced efficacy of immune checkpoint inhibitors (ICIs) in cancer therapy. The research, led by Desharnais and colleagues, identifies the bacterium Lactobacillus johnsonii (search) and its tyrosine-derived metabolite desaminotyrosine (DAT) as central mediators of this diet–microbiome–immunity axis.
The findings carry significant translational implications, suggesting that dietary and microbial interventions could be strategically deployed to boost immunotherapy outcomes, particularly in patients with obesity or those harboring compromised gut microbiomes.
Obesogenic Diets Enrich L. johnsonii and Drive ICI Response
Metagenomic sequencing of fecal samples from mice consuming various diets revealed that L. johnsonii was the top enriched bacterial species associated with response to anti-PD-1 therapy. This enrichment was consistently observed in mice fed obesogenic, ICI-responsive diets—specifically High Fat and American-style regimens—compared with non-responder diets such as Ketogenic and Mediterranean formulations.
To establish causality, the research team performed monocolonization experiments in germ-free mice maintained on a High Fat diet. The combination of High Fat diet with L. johnsonii resulted in a striking anti-tumor effect following anti-PD-1 treatment. In antibiotic-treated specific pathogen-free mice fed a High Fat diet, L. johnsonii supplementation led to complete responses in all mice treated with anti-PD-1—an effect not observed with control PBS gavage.
Crucially, the study demonstrated that diet and microbiota must align for optimal benefit. Colonization with a top non-responder species (M. gordoncarteri) in mice on a High Fat diet, or colonization with L. johnsonii in mice fed the non-responder Psyllium diet, conferred only partial sensitivity. "Only the combination of High Fat with L. johnsonii induced tumour clearance, indicating a synergistic interaction between diet and microbiota," the authors note.
Diet Overrides Donor Microbiota Characteristics
In a striking demonstration of diet's dominant role, the researchers performed fecal microbiota transplantation (FMT) using donor stool from an ICI-non-responder patient with lung cancer into recipient mice on either a Psyllium or High Fat diet. Mice on the Psyllium diet remained insensitive to anti-PD-1, consistent with the donor's non-responder status. However, mice on the High Fat diet were sensitized to anti-PD-1 despite receiving the same donor microbiota. This diet-driven rescue was associated with increased L. johnsonii abundance in the stool of High Fat-fed mice.
DAT: A Microbial Metabolite That Restores Immunotherapy Sensitivity
Untargeted metabolomics on serum from diet-treated mice identified aromatic amino acid metabolism—particularly tryptophan and tyrosine pathways—among the top enriched metabolic signatures in responders. The microbial phenylpropionate metabolite desaminotyrosine (DAT), a tyrosine-derived compound produced by L. johnsonii, emerged as a key immunomodulator.
Serum DAT levels were significantly higher in L. johnsonii-monocolonized mice consuming a High Fat diet compared with those on a Psyllium diet, and DAT remained low in germ-free mice on a High Fat diet without L. johnsonii, confirming its microbial origin. DAT concentrations were also elevated in supernatants from live L. johnsonii cultures compared with controls.
Ex vivo experiments demonstrated that DAT supplementation potentiated CD8+ T cell effector responses, with elevated production of IFNγ and TNF. When T cells were primed with both fecal homogenate and DAT together, the strongest enhancement of effector molecule production was observed.
Most compellingly, in vivo administration of DAT to mice on the non-responder Psyllium diet restored sensitivity to anti-PD-1 immunotherapy. "DAT supplementation was sufficient to reverse this effect and sensitize mice to therapy," the researchers report, confirming DAT's functional role in overcoming diet-induced resistance.
Translational Evidence in NSCLC Patients
Plasma metabolomics from a cohort of 53 patients with non-small cell lung cancer (search) (NSCLC) undergoing ICI treatment revealed that responders exhibited elevated levels of tryptophan and phenylpropionate metabolites, including indole-3-lactic acid (ILA) and 3-hydroxy-3-(3-hydroxyphenyl) propionic acid-O-sulfate—a host-conjugated correlate of DAT within the same phenylpropionate metabolic axis.
Furthermore, FMT experiments using fecal material from low-BMI (BMI < 25) and high-BMI (BMI ≥ 25) donors demonstrated that a significant effect of anti-PD-1 was observed in mice receiving FMT from high-BMI donors, whereas no effect was observed following FMT from low-BMI donors. Notably, the few responding mice within the low-BMI group all received FMT from a single donor whose BMI (24.95) was near the threshold for overweight classification.
Clinical Implications and Future Directions
This study establishes a mechanistic framework linking obesogenic diets, specific gut microbes, and amino acid-derived metabolites that synergize to enhance cancer immunotherapy. The identification of L. johnsonii and DAT as functional mediators opens potential avenues for dietary interventions, probiotic supplementation, or metabolite-based therapeutics aimed at improving ICI outcomes.
The research underscores that both diet and microbiome composition must be considered in optimizing immunotherapy strategies, and that dietary context can potentially override unfavorable microbiota profiles to restore therapeutic sensitivity.